Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria-Reference-Cited by-同舟云学术

Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria

Published:2010-05-05 Issue:8 Volume:85 Page:553-559
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Hillmen Peter,Elebute Modupe,Kelly Richard,Urbano-Ispizua Alvaro,Hill Anita,Rother Russell P.,Khursigara Gus,Fu Chieh-Lin,Omine Mitsuhiro,Browne Paul,Rosse Wendell

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.21757/fullpdf

Reference37 articles.

1. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease;Rother;JAMA,2005

2. Natural history of paroxysmal nocturnal hemoglobinuria;Hillmen;N Engl J Med,1995

3. Diagnosis and management of paroxysmal nocturnal hemoglobinuria;Parker;Blood,2005

4. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria;Takeda;Cell,1993

5. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology;Socie;Lancet,1996

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms;Drug Discovery Today;2024-09

2. Advances in research on renal injury in paroxysmal nocturnal hemoglobinuria;Journal of Investigative Medicine;2024-08-28

3. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval;International Journal of Molecular Sciences;2024-08-09

4. CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation;Blood Advances;2024-08-02

5. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors;PLOS ONE;2024-07-29